Indonesia is one of those emerging markets that has pressured outside companies to produce locally and companies like Pfizer, Merck and Fresenius Kabi have all built or expanded plants there in recent years. But the government, which controls some of the players, is taking steps to improve efficiency in the domestic market, pushing for a merger that ties the manufacturing expertise of one company to the supply chain strength of another.
Indonesia is one of the rapidly growing markets that drugmakers are trying to tap to boost sales, and GlaxoSmithKline is upping its bet. The U.K.-based drugmaker said today it will buy full control of its consumer health unit there.
Pfizer, which boosted production at its plant in Indonesia in 2012, is expanding there again.
The generics division of the German healthcare company has bought controlling interest in Indonesian drugmaker PT Ethica Industri Farmasi from PT Soho Global Healthcare. The two will build a $60 million plant to make IV generic drugs and infusion solutions and make Fresenius Kabi the market leader in IV generics in Indonesia.
Germany's Fresenius Kabi has decided to expand into Southeast Asia with a plant in Indonesia to make intravenous drugs, buying controlling interest in Indonesian drugmaker PT Ethica Industri Farmasi from PT Soho Global Healthcare.
Sources tell The Wall Street Journal that the deal could be worth $200 million.
Last year Sanofi boss Chris Viehbacher ran out his list of his favorite emerging market opportunities including Colombia, Indonesia and Vietnam. A new rundown on recent developments in Vietnam, show the many reasons why Viehbacher would see the southeast Asian country as a very good bet.
While Quintiles has been active in Indonesia since 2006, it has never been able to involve the country in a global clinical trial. That's all changing thanks to a partnership with Indonesia's Prodia Clinical Laboratory.
Asia is becoming a danger zone for pharma's intellectual property. On the heels of India's first compulsory licensing move, Indonesia has nixed patent protection on 7 HIV fighters and hepatitis drugs. The move would open the gates to cheap generic rivals, expanding access--and cutting into sales of pharma's brand names.
Merck ($MRK) has opened a $21 million packaging plant in Indonesia, expecting to tap growth in Asian markets.